Actavis (ACT) to Release Earnings on Tuesday
Actavis (NYSE:ACT) is set to post its Q313 quarterly earnings results on Tuesday, October 29th. Analysts expect Actavis to post earnings of $2.09 per share and revenue of $2.04 billion for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Actavis (NYSE:ACT) opened at 148.15 on Monday. Actavis has a 52-week low of $80.81 and a 52-week high of $139.10. The stock’s 50-day moving average is $135.2 and its 200-day moving average is $116.2. The company’s market cap is $19.726 billion.
A number of analysts have recently weighed in on ACT shares. Analysts at Citigroup Inc. initiated coverage on shares of Actavis in a research note to investors on Friday. They set a “buy” rating and a $172.00 price target on the stock. On the ratings front, analysts at TheStreet downgraded shares of Actavis from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, October 22nd. Finally, analysts at Susquehanna raised their price target on shares of Actavis from $140.00 to $165.00 in a research note to investors on Monday, October 21st. They now have a “neutral” rating on the stock. Six research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $148.83.
Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.